Sanofi (NYSE:SNY) and Voluntis said today that the groups inked a non-exclusive agreement to bring digital insulin management systems for Type II diabetes to the U.S. and several European countries.
The companies 1st established in alliance in 2011, developing a mobile phone application that was designed to improve decision-making and self-management of patients with Type II diabetes treated with basal insulin.
Get the full story at our sister site, Drug Delivery Business News.
The post Sanofi, Voluntis ink deal for digital insulin management system for T2D appeared first on MassDevice.